Evidence map›Paper›PMID 40876822›Full record

SynthesisRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin2026

Extending the Age Range in Mammography Screening: A Benefit-Risk Assessment from a Radiation Protection Perspective.

Theresa Hunger, Elke Anna Nekolla, Eva Wanka-Pail, Katharina Stella Winter, Gunnar Brix

Abstract readMeta-AnalysisSystematic ReviewReview
In one paragraph

Synthesis in RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Theresa HungerMedical and Occupational Radiation Protection, Federal Office for Radiation Protection, Neuherberg, Germany.ORCID 0000-0003-2771-5092
Elke Anna NekollaMedical and Occupational Radiation Protection, Federal Office for Radiation Protection, Neuherberg, Germany.
Eva Wanka-PailMedical and Occupational Radiation Protection, Federal Office for Radiation Protection, Neuherberg, Germany.
Katharina Stella WinterMedical and Occupational Radiation Protection, Federal Office for Radiation Protection, Neuherberg, Germany.
Gunnar BrixMedical and Occupational Radiation Protection, Federal Office for Radiation Protection, Neuherberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammography screening programs (MSP) are established for women age 50 to 69 years in Germany and Europe. Some of the studies that build the evidence base for these programs also included women who were younger or older than this target population. The aim of our study was to assess whether screening also provides more benefit than harm to women outside the originally defined age range of the German MSP.A systematic review and meta-analysis of randomized controlled trials (RCT) was performed to assess overall and breast cancer mortality in women older than 70 years and women under 50 years. Radiation-associated age-specific lifetime attributable risks (LAR) were estimated based on a modified risk model of the BEIR Committee using current cancer and lifetime data for a female German population.Two RCTs with 33,268 women age 70 years or older, and eight RCTs with 394,080 women age 39-49 years were included. The relative reduction in breast cancer mortality was 28% (risk ratio (RR) = 0.72; 95% confidence interval (CI): 0.54-0.95) and 18% (RR = 0.82; 95%-CI: 0.71-0.96), respectively. The proportion of overdiagnoses in older women is estimated at 19% and is higher than in younger women. Assuming biennial screening from below 50 to 69 years of age, the LAR decreases considerably with increasing age at start of screening, being 0.06%, 0.04%, and 0.025% when starting at 40, 45, or 50 years, respectively. The corresponding benefit-risk ratios are about 25, 35, and 45, respectively. Changing the upper screening age to 75 has little impact on the benefit-risk ratio.Extending the age limits in MSP to women starting from 45 years and up to 75 years is justified from the radiation perspective since the benefit substantially outweighs the radiation risk. Based on our report, the MSP has also been approved for women age 70 to 75 in Germany as of February 2024, while it is still pending for younger women. · Screening can reduce breast cancer mortality in women age 45-49 and 70-75.. · As a result, more women can benefit from mammography screening programs.. · The downside for older women is more overdiagnoses.. · Younger women face a higher radiation risk.. · Hunger T, Nekolla EA, Wanka-Pail E et al. Extending the Age Range in Mammography Screening: A Benefit-Risk Assessment from a Radiation Protection Perspective. Rofo 2026; 198: 164-172.

Indexed as

Breast NeoplasmsEarly Detection of CancerMammographyMass ScreeningRadiation ProtectionAdultAgedAge FactorsFemaleGermanyHumansMiddle AgedNeoplasms, Radiation-InducedOverdiagnosisRandomized Controlled Trials as TopicRisk Assessment

Identifiers

PMID40876822
PMCPMC12851822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.